利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.029 秒)

    Method for producing light emitting diode device
    2.
    发明授权
    Method for producing light emitting diode device 有权
    发光二极管装置的制造方法

    公开(公告)号：US08551277B2

    公开(公告)日：2013-10-08

    申请号：US13597341

    申请日：2012-08-29

    申请人： Yasunari Ooyabu ,  Hiroyuki Katayama ,  Daisuke Tsukahara ,  Munehisa Mitani

    发明人： Yasunari Ooyabu ,  Hiroyuki Katayama ,  Daisuke Tsukahara ,  Munehisa Mitani

    IPC分类号： H01L33/00

    CPC分类号： H01L33/52 ,  H01L2933/005

    摘要： A method for producing a light emitting diode device includes the steps of preparing a laminate including, in order, a supporting layer, a constraining layer and an encapsulating resin layer, each formed in a thickness direction; cutting the encapsulating resin layer and the constraining layer in the laminate into a pattern corresponding to the light emitting diode element; removing a portion which does not correspond to the light emitting diode element in the encapsulating resin layer and the constraining layer that are cut into the pattern; allowing the encapsulating resin layer corresponding to the light emitting diode element to be opposed to the light emitting diode element to be pressed in the direction where they come close to each other so as to encapsulate the light emitting diode element by the encapsulating resin layer; and removing the supporting layer and the constraining layer from the laminate.

    摘要翻译： 一种发光二极管器件的制造方法，其特征在于，具有如下工序：在厚度方向上形成有依次层叠的支撑层，约束层和密封树脂层。 将层压体中的封装树脂层和约束层切割成对应于发光二极管元件的图案; 去除与切割成图案的封装树脂层和约束层中的发光二极管元件不对应的部分; 使与发光二极管元件相对应的封装树脂层与发光二极管元件相对，以使它们彼此靠近的方向被按压，以便通过封装树脂层封装发光二极管元件; 并从层叠体上除去支撑层和约束层。

    2-heteroaryl-substituted benzimidazole derivative
    4.
    发明授权
    2-heteroaryl-substituted benzimidazole derivative 有权
    2-杂芳基取代的苯并咪唑衍生物

    公开(公告)号：US07728025B2

    公开(公告)日：2010-06-01

    申请号：US10582564

    申请日：2004-12-28

    申请人： Katsumasa Nonoshita ,  Makoto Ishikawa ,  Hiroshi Nakashima ,  Daisuke Tsukahara ,  Yoshio Ogino ,  Fumiko Sakai ,  Yoshikazu Nagae ,  Keisuke Arakawa ,  Teruyuki Nishimura

    发明人： Katsumasa Nonoshita ,  Makoto Ishikawa ,  Hiroshi Nakashima ,  Daisuke Tsukahara ,  Yoshio Ogino ,  Fumiko Sakai ,  Yoshikazu Nagae ,  Keisuke Arakawa ,  Teruyuki Nishimura

    IPC分类号： A01N43/50

    CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D401/12 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04

    摘要： A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided.A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt: [in the formula, X represents a carbon atom or a nitrogen atom; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II): (in the formula, X represents a carbon atom or a nitrogen atom); R1 represents an aryl, etc.; R2 represents a hydroxy, etc.; R3 represents a —C1-6 alkyl, etc.; R4 represents a —C1-6 alkyl, etc.; X5 represents —O—, etc.; a indicates an integer of 1, 2 or 3; q indicates an integer of from 0 to 2; m indicates an integer of from 0 to 2].

    摘要翻译： 提供葡糖激酶活化剂; 提供了糖尿病的补救措施和/或预防，糖尿病的补救和/或预防，如视网膜病变，肾病，神经症，缺血性心脏病，动脉硬化，以及进一步的补救措施和/或预防肥胖症。 一种葡糖激酶活化剂，其特征在于含有通式（I-0）的2-杂芳基取代的苯并咪唑衍生物或其药学上可接受的盐：[式中X表示碳原子或氮原子; X1，X2，X3和X4各自独立地表示碳原子或氮原子; 环A表示式（II）的5-或6-元含氮芳族杂环：（式中，X表示碳原子或氮原子）; R1表示芳基等。 R2代表羟基等; R3代表-C 1-6烷基等; R4代表-C 1-6烷基等; X5表示-O-等。 a表示1,2或3的整数; q表示0〜2的整数， m表示0〜2的整数]。

    Carbamoyl-Substituted Spiro Derivative
    5.
    发明申请
    Carbamoyl-Substituted Spiro Derivative 有权
    氨基甲酰取代的螺衍生物

    公开(公告)号：US20080171753A1

    公开(公告)日：2008-07-17

    申请号：US11662102

    申请日：2005-09-06

    申请人： Makoto Jitsuoka ,  Norikazu Ohtake ,  Nagaaki Sato ,  Shigeru Tokita ,  Daisuke Tsukahara

    发明人： Makoto Jitsuoka ,  Norikazu Ohtake ,  Nagaaki Sato ,  Shigeru Tokita ,  Daisuke Tsukahara

    IPC分类号： A61K31/497

    CPC分类号： C07D307/94 ,  C07D209/96 ,  C07D401/12 ,  C07D405/08 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/04 ,  C07D491/10 ,  C07D493/10

    摘要： A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R6 represents a lower alkyl, etc; and R7 and R8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

    摘要翻译： 化合物。 式（I）：[其中X，Y，Z和W各自独立地表示任选取代的次甲基; A，B和D各自独立地表示-C（O） - 等; Q表示次甲基或氮; 并且R代表式（II-1），任选被低级烷基取代等; （其中R 6表示低级烷基等; R 7和R 8各自独立地表示低级烷基等）]或 化合物的药学上可接受的盐。 化合物和盐对组胺H3受体具有拮抗作用或对组胺H3受体具有反向激动作用。 它们可用于预防或治疗代谢疾病，循环系统疾病或神经病。

    Conditional access system enabling partial viewing
    6.
    发明授权
    Conditional access system enabling partial viewing 失效
    有条件的访问系统，使部分观看

    公开(公告)号：US06920222B1

    公开(公告)日：2005-07-19

    申请号：US09641512

    申请日：2000-08-18

    申请人： Daisuke Tsukahara ,  Yasutaka Akita ,  Susumu Oka ,  Tokumichi Murakami ,  Yukinari Matsuda

    发明人： Daisuke Tsukahara ,  Yasutaka Akita ,  Susumu Oka ,  Tokumichi Murakami ,  Yukinari Matsuda

    IPC分类号： H04N7/16 ,  H04N21/266 ,  H04N21/462 ,  H04N21/4623 ,  H04N7/167

    CPC分类号： H04N21/26606 ,  H04N7/163 ,  H04N7/1675 ,  H04N21/44055 ,  H04N21/4623

    摘要： A conditional access system includes an EMM (Entitlement Management Message) analyzer for retrieving partial viewing authorization information. When the partial viewing authorization information permits partial viewing, ECM (Entitlement Control Message) is decrypted using work keys, and scrambling keys are intermittently retrieved from the ECM. This can solve a problem of a conventional conditional access system in that an unauthorized user's receiver cannot display pictures at all because the receiver cannot retrieve scrambling keys, and hence the user cannot enjoy a program even to such a degree as to perceive its feeling as in analog broadcasting systems, and thus the user cannot decide as to whether to make contract or not with viewing the program to some extent, which prevents the provider of the program from offering effective invitation to the user.

    摘要翻译： 条件访问系统包括用于检索部分查看授权信息的EMM（授权管理消息）分析器。 当部分观看授权信息允许部分观看时，使用工作密钥来解密ECM（授权控制消息），并且从ECM间歇地检索加扰密钥。 这可以解决传统的条件访问系统的问题，因为未经授权的用户的接收机根本无法显示图像，因为接收机不能检索加扰密钥，因此用户甚至不能享受程序，以便感觉到其感觉如 模拟广播系统，因此用户不能在一定程度上决定是否通过观看节目进行合同，这阻止了节目的提供者向用户提供有效的邀请。

    Aza-substituted spiro derivatives
    8.
    发明授权
    Aza-substituted spiro derivatives 有权
    氮杂取代的螺衍生物

    公开(公告)号：US08158791B2

    公开(公告)日：2012-04-17

    申请号：US12084817

    申请日：2006-11-10

    申请人： Makoto Jitsuoka ,  Nagaaki Sato ,  Daisuke Tsukahara

    发明人： Makoto Jitsuoka ,  Nagaaki Sato ,  Daisuke Tsukahara

    IPC分类号： A61K31/44 ,  A61K31/34 ,  A61K31/335 ,  C07D221/00

    CPC分类号： C07D491/10

    摘要： A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH2)m2-, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R6, R7 and R8 independently represent a lower alkyl group or the like].

    摘要翻译： 提供下式（I）的化合物或其药学上可接受的盐：[其中X，Y，Z和W各自独立地表示次甲基或氮原子，条件是X，Y，Z全部为 W是次甲基; A表示-O-等，B表示-C（O） - 等，D表示 - （CH2）m2-，-O-等，m2表示0或1; Q表示次甲基或氮原子; 并且R表示由下式（II-1）表示的基团（其中R 6，R 7和R 8独立地表示低级烷基等）。

    Carbamoyl-substituted spiro derivative
    9.
    发明授权
    Carbamoyl-substituted spiro derivative 有权
    氨基甲酰取代的螺衍生物

    公开(公告)号：US07960402B2

    公开(公告)日：2011-06-14

    申请号：US11662102

    申请日：2005-09-06

    申请人： Makoto Jitsuoka ,  Norikazu Ohtake ,  Nagaaki Sato ,  Shigeru Tokita ,  Daisuke Tsukahara

    发明人： Makoto Jitsuoka ,  Norikazu Ohtake ,  Nagaaki Sato ,  Shigeru Tokita ,  Daisuke Tsukahara

    IPC分类号： A61K31/44 ,  A61K31/34 ,  A61K31/335 ,  C07D401/00 ,  C07D307/00

    CPC分类号： C07D307/94 ,  C07D209/96 ,  C07D401/12 ,  C07D405/08 ,  C07D405/12 ,  C07D405/14 ,  C07D471/10 ,  C07D487/04 ,  C07D491/10 ,  C07D493/10

    摘要： A compound represented by, e.g. the formula (I): [wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.; (wherein R6 represents a lower alkyl, etc; and R7 and R8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.

    摘要翻译： 化合物。 式（I）：[其中X，Y，Z和W各自独立地表示任选取代的次甲基; A，B和D各自独立地表示-C（O） - 等; Q表示次甲基或氮; 并且R代表式（II-1），任选被低级烷基取代等; （其中R6表示低级烷基等; R7和R8各自独立地表示低级烷基等）]或化合物的药学上可接受的盐。 化合物和盐对组胺H3受体具有拮抗作用或对组胺H3受体具有反向激动作用。 它们可用于预防或治疗代谢疾病，循环系统疾病或神经病。